Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India's New IPR Policy: Balanced And Evolving?

Executive Summary

India new National Intellectual Property Rights (IPR) policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".

You may also be interested in...

Novartis' Zia On Momentum Amid Policy Strain In India

As Novartis continues to battle Glivec-related pain in India, its country president Jawed Zia tells Scrip that the Swiss multinational has been hit "particularly hard" after the government withdrew customs duty exemptions on more than 70 drugs including imatinib mesylate earlier this year.

India's National IPR policy: what's cooking?

India appears to be on course to releasing its National Intellectual Property Rights (IPR) policy but some industry experts say they are concerned that, despite seeming assurances, concessions around "patent linkage" and "data exclusivity" may find their way into the final framework.

Speedy dispute resolution on Indian IPR policy agenda

India's draft national intellectual property rights (IPR) policy, which appears to steer clear from very radical suggestions, is aiming to strengthen the enforcement and adjudicatory mechanisms for combating IP violations, piracy and counterfeiting to facilitate effective and quick resolution of disputes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts